Ronan J Kelly, Katherine Bever, Joseph Chao, Kristen K Ciombor, Cathy Eng, Marwan Fakih, Lipika Goyal, Joleen Hubbard, Renuka Iyer, Holly T Kemberling, Smitha Krishnamurthi, Geoffrey Ku, Mindy Mintz Mordecai, Van K Morris, Andrew Scott Paulson, Valerie Peterson, Manish A Shah, Dung T Le
Gastrointestinal (GI) cancers, including esophageal, gastroesophageal junction, gastric, duodenal and distal small bowel, biliary tract, pancreatic, colon, rectal, and anal cancer, comprise a heterogeneous group of malignancies that impose a significant global burden. Immunotherapy has transformed the treatment landscape for several GI cancers, offering some patients durable responses and prolonged survival. Specifically, immune checkpoint inhibitors (ICIs) directed against programmed cell death protein 1 (PD-1), either as monotherapies or in combination regimens, have gained tissue site-specific regulatory approvals for the treatment of metastatic disease and in the resectable setting...
June 2023: Journal for Immunotherapy of Cancer